Key Clinical Trial Findings:

• The individualized schedule mitigated mechanism-based anemia based on entry hemoglobin observed in a minority of patients
• Overall clinical benefit was maintained after schedule change with generally maintained radiographic regressions and molecular responses:
  - Despite the change in schedule, deepening of target lesion regression was noted in some patients
  - After 9 weeks on therapy, there was no observed impact on Progression Free Survival (PFS) in patients who started on or switched to the schedule of 2 weeks on / 1 week off of treatment
• Dose optimization meaningfully reduced Grade 3 anemia (22.6% vs. 51.4%, previously) in all patients:
  - Baseline marrow function was the key reason for Grade 3 anemia as opposed to exposure to therapy
  - Baseline hemoglobin, prior therapies, and treatment intensity (weekly vs. 2 weeks on / 1 week off) predicted Grade 3 anemia frequency with lunre+camo
  - Anemia reduction was greatest in patients with baseline hemoglobin less than 11g/dL (Grade 3 anemia at week 12: 34% vs. 68%, previously; overall risk reduction: 58%)
  - Red blood cell transfusions (13% vs. 43%, previously), dose interruptions (13% vs. 23%) and dose reductions (6% vs. 17%) were also reduced with the new schedule
  - Other Grade 3 events were already uncommon (<5% incidence) and remained consistently low, regardless of schedule.